All In MedTech

Device Trial Radar · NCT05016076

Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial

The Multi-Strategy Intervention to Enhance Quality of Anesthesia Care for Obese Patients: A Factorial Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 2022

Primary completion

Aug 2023

Study completion Aug 2023

Sponsor

Lead sponsor
YingHsuanTaiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 23, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Factorial
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to investigate the optimal anesthesia for obese patients undergoing bariatric surgery in the strategies of positive pulmonary ventilation, tracheal intubation technique, hemodynamic monitoring, and postoperative nausea and vomiting (PONV) prophylaxis, as the followed: 1. To evaluate the effectiveness and adverse effect of intravenous dexamethasone for PONV prophylaxis 2. To determine the safe inspiratory pressure to prevent the occurrence of gastric insufflation during facemask ventilation using point-of-care ultrasonography of antrum 3. To compare the effectiveness and safety between video intubating stylet and video laryngoscope in the placement of tracheal tubes 4. To apply minimally invasive CO monitors in guiding goal-directed hemodynamic therapy and assess its impact on major complications and postoperative recovery

Conditions

  • Obesity
  • Bariatric Surgery Candidate
  • Tracheal Intubation Morbidity
  • Nausea and Vomiting, Postoperative
  • Hyperglycemia Drug Induced
  • Gastric Reflux

Interventions

  • Dexamethasone 8 mgDrug

    In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia.

  • Applied inspiratory pressure (10, 15, 20, or 25 cmH2O)Diagnostic test

    A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea determined by end-tidal capnography occurs, a mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure (PEEP), at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator (Carestation 620, Datex-Ohmeda, Inc., Madison, WI, USA).

  • Tracheal intubation using video intubating stylet, video laryngoscopy, or direct laryngoscopyDevice

    In video intubating stylet group, a tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved. In video laryngoscopy group, a tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients. In direct laryngoscopy group, tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).

  • Goal-directed hemodynamic therapy targeting cardiac indexDevice

    Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2. In brief, if cardiac index \< 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is \< 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.

  • Placebo (0.9% sodium chloride)Drug

    Placebo of 0.9% sodium chloride will be given intravenously within 10 minutes after the induction of anesthesia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Substudy 1: Number of participants developing postoperative nausea and vomitingTime frame: The first 24 postoperative hour
  2. Substudy 2: The threshold inspiratory pressure for gastric insufflationTime frame: Within 2 min after induction of anesthesia
  3. Substudy 3: The best glottis visualization, graded according to Cormack and Lehane's classificationTime frame: From the induction of anesthesia to the 24th postoperative hours

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shuang Ho Hospital, Taipei Medical University

    New Taipei City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.